Introduction

Neopterin is a substance having low molecular weight (253.22), which is excreted by the kidneys. Neopterin was determined in bee larva in 1963 for the first time (20). The first determination in humans was found in urine with a study carried out in 1967 (21). High neopterin leap was noted in the urine of patients with viral infections and malignities in 1979 (24). Since neopterin generally remains stable in the body fluids, it is not usually difficult to measure neopterin levels by routine laboratory tests. Neopterin concentration can be used to determine the activation of cellular immune response. Some pathologies in which urinal neopterin increase could be observed, are viral infections (acute hepatitis A and B, mononucleosis, cytomegalovirus, measles, HIV) (6,7,9,14) and infections with intercellular bacteria and parasites (tuberculosis, leprosy, melioidosis, malaria and schistosomiasis) (2,5,16,23,27), autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, multiple sclerosis) (4,11,17,22) allograft rejections (10), malignant diseases. An increment in urinal neopterin was determined among gynecological cancers, particularly in ovarian cancer (13,19). At tumoral stages, some significant relations of neopterin level were detected. In cervical Ca, lower neopterin level has been observed than the one in ovarian cancer (50–60%) (15).

Cervico-vaginal cytology (smear) is exfoliative cytological technique (1). However cytology is not a certain evidence to the existing disease, but rather a guide to the other methods such as colposcopy and histopathology. In other
words, it is a kind of medical consultation. The function of the cytology is to schedule the clinical and laboratory operations required for the patient. The advantages of smear are easiness of sampling and inspection, repeatability and diagnosis with high correctness. All these advantages make the smear test be used as a screening method in the world widely. Papanicolau showed that cervico-vaginal cytology can be used in the diagnosis of cervical cancer (12).

This prospective clinical study was performed to investigate the importance of urinal neopterin detection done together with cervical smear test, in the diagnosis of cervical cancer.

**Material and methods**

**Patients**

The study was based on 90 female patients allocated into three groups.

1st Group: 35 women who suffered from vulvovaginitis, and whose ages varied from 21 to 42. They attended to the Gynecology and Obsterics Polyclinic of the Faculty of Medicine-Kirikkale University and Kalecik State Hospital with a complaint of vaginal discharge. They had no viral infections and any other chronic inflammatory diseases and they were none-smokers.

2nd Group: 25 women aged between 38 and 52, who applied to the clinic with complaints of vaginal discharge, and the cervical cancer was diagnosed for them as the result of biopsy, but no associated treatment of cancer had been carried out yet. They were also non-smokers and they didn’t have any chronic inflammatory diseases, and viral infections. Standardization of the study, only the cervical cancer patients with stage I according to FIGO 1998 were included to this group.

3rd Group was formed as a control group. For this group, 30 healthy women whose ages varied from 20 to 28 were randomly selected. They were non-smokers, and who had not taken part in sexual activities yet. They had no complaints from any type of tumors, and viral infections or chronic inflammatory diseases.

**Pathological procedure**

Smears are taken from the patients with cytobrush at optimal conditions. They were examined carefully by one cytopathologist and the results were obtained by Bethesda system. Biopsies were done from multiple focuses under colposcopy by using punch (Kevorkian) biopsy pens and the materials were sent to a pathologist in %10 formalin solution.

**Laboratory examination**

Urine samples were taken from all group members to measure the levels of neopterin. From all members, urine samples were taken as their first excretion early in the morning when they started attending hospital for routine tests. Because of the light sensitivity of neopterin, the specimens were protected from direct sunlight during transport and storage. All the samples were kept in a light-proof containers at -20 C until the time that they would be analyzed. The measurements were taken with the methods described by Fuchs3. A – Hewlett Packard-1050 USA- was employed as the High Performance Liquid Chromatography (HPLC) instrument, and as the analytic column, an (Allsphere ODS-2 Reverse-Phase column Alltech, Deerfield, IL, USA) and as the guard column a (Spherisorb ODS-2 Cartridge Alltech, Deerfield, IL, USA) were employed for the analyses at GATA Biochemistry and Clinical Biochemistry Laboratories. The results were calculated as neopterin/creatinine content for each sample and reported in terms of mol/mol.

**Statistical analysis**

Interpretation of urinary neopterin/creatinine ratios were done under SPSS Windows 10.0. The neopterin levels of the two sample groups (Group 1 and 2) and the control group (Group 3) were assessed by Oneway Annova test. (p=0.000) The differences of between the group results were determined by the Post Hoc Tukey Test.

**Results**

Urinary neopterin levels of three test groups are tabulated below in Table 1, and the test results illustrated in Fig. 1.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Neopterin µmol neopt/mol cre Median (min – max)</th>
<th>Standard deviation (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. group (n=35)</td>
<td>198.4 (87.3–314.2)</td>
<td>56.6</td>
</tr>
<tr>
<td>2. group (n=25)</td>
<td>559.6 (134.7–1407.0)</td>
<td>340.3</td>
</tr>
<tr>
<td>3. group (n=30)</td>
<td>94.9 (54.0–147.3)</td>
<td>25.1</td>
</tr>
</tbody>
</table>

**Pathological results**

1st Group: The smear results of 35 patients with vulvovaginitis revealed inflammation. The biopsy results of all the members of this group were normal.
Discussion

The increasing amount of urinary neopterin in malignant diseases and viral infections could be attributed to the facts that the cellular growth and cellular proliferation occur with the formation of neopterin, thus causing the leap in its concentration. So that no change in neopterin concentration can be observed in benign tumors. The study in 1981 has shown that neopterin formation occurs with the activation of cellular immune system (24).

Since neopterin is produced in cells of the immune system, but not by tumor cells, neopterin is not a tumor marker per se. T-cell activation, which is probably induced by malignant transformed cells, leads to cytokine production, macrophage activation and ultimately, neopterin release. The sensitivity of the neopterin test is greatly dependent on the localization of the malignant disease (18).

The strength of neopterin testing does not lie in tumor screening, but in determination of the prognosis and in monitoring of therapy results in patients with malignant diseases (15,25). Neopterin testing therefore seems to suggest itself as a supplementary monitoring method in tumor follow-up, in which case an increase in the neopterin concentration indicates the necessity to initiate further diagnostic measures. The neopterin concentration can also be used as an additional indicator for differentiation between benign and malignant tumors.

As long as renal functions is more or less normal, serum and urinary neopterin measurements are comparably sensitive for detection of disease developments associated with the activation of cellular immune system. The neopterin concentration in the urine is assessed according to the creatinin levels. In some previous studies, urinal neopterin concentration was found with a mean level of 128±33µmol neopterin/mol creatinin among women aged between 19 and 25, and 124±33 µmol neopterin/mol creatinin among women aged between 26 and 35. 140±33 µmol neopterin/mol creatinin among women aged between 36 and 45. 147±32 µmol neopterin/mol creatinin among women aged between 46 and 55, 156±35 µmol neopterin/mol creatinin among women aged between 56 and 65, and finally 141±40 µmol neopterin/mol creatinin among the ones aged more than 65 (26).

In this study, the differences in the levels of neopterin concentration classified according to the ages of women seemed to be in accordance with the above findings. Furthermore, the results of Group 2 showed that in spite of the influence of age, the tumoral effect also played an important role in the level of neopterin concentration.

The incidence of increased neopterin in cervical cancer (Ca) is 50–60% (15). In the diagnosis of cervical Ca, the sensitivity of smear was found to be 60–80% and pseudo-negativity was notified as to be 20–40% (8). In the diagnosis of cervical Ca, the algorithm are smear, colposcopy and biopsy. In this algorithm, the sensitivity of smear is 60–80% (8).

In our study, cervical cancer case was observed with the incidence of 27.7%. In Group 2, the malignancy was diagnosed with a rate of 32% by cervical smear test. In literature survey, this ratio seems to be 60–80%. When we compared the levels of neopterin concentration of Group 2 with the normal values (of the Control Group) the levels seemed to be high in 88% of the group findings. This increment was also statistically meaningful among the members of Group 1, the neopterin concentrations were high with the rate of 60. When the results of Group 1 and Group 2 were compared with each other, there seemed to be a statistically significant relationship among them.

In this study we have not determined the sensitivity and specificity of urinary neopterin, because it required a large number of patients to be detected.

If the results of this study were not confounded by another factor, then we can deduce that increment in the level of neopterin concentration may be considered as a risk factor that should warrant further investigation of cervical cancer. Then, the detection of urinal neopterin level as a noninvasive test together with cervical smear can increase the efficiency of smear test.

References


Merih Bayram, M.D., Bilkent I, D: 4 No: 9, Bilkent-Ankara 06530, Turkey. e-mail: merbay@ttinet.net.tr